Figure 3From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues Tumour-to-non-target ratios. (a) Tumour-to-blood, (b) tumour-to-pancreas, (c) tumour-to-kidney and (d) tumour-to-liver ratios.Back to article page